APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ustekinumab Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Ustekinumab Biosimilars Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchUstekinumab Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Ustekinumab Biosimilars Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Ustekinumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ustekinumab Biosimilars Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ustekinumab Biosimilars Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Ustekinumab Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Ustekinumab Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ustekinumab Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Ustekinumab Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ustekinumab Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Ustekinumab Biosimilars include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions and Huadong Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ustekinumab Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ustekinumab Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Ustekinumab Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ustekinumab Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ustekinumab Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Ustekinumab Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Ustekinumab Biosimilars Segment by Company

Teva

Amgen

Samsung Bioepis

Sandoz

Biocon Biologics

Celltrion

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Ustekinumab Biosimilars Segment by Type

Subcutaneous Injection

Intravenous Infusion

Ustekinumab Biosimilars Segment by Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Ustekinumab Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ustekinumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ustekinumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ustekinumab Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Ustekinumab Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Ustekinumab Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ustekinumab Biosimilars sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ustekinumab Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Subcutaneous Injection Major Manufacturers Table 3. Intravenous Infusion Major Manufacturers Table 4. Global Ustekinumab Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Crohn's Disease Major Manufacturers Table 6. Ulcerative Colitis Major Manufacturers Table 7. Plaque Psoriasis Major Manufacturers Table 8. Psoriatic Arthritis Major Manufacturers Table 9. Other Major Manufacturers Table 10. Ustekinumab Biosimilars Industry Trends Table 11. Ustekinumab Biosimilars Industry Drivers Table 12. Ustekinumab Biosimilars Industry Opportunities and Challenges Table 13. Ustekinumab Biosimilars Industry Restraints Table 14. Global Ustekinumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Ustekinumab Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Ustekinumab Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Ustekinumab Biosimilars Revenue Market Share by Region (2021-2026) Table 18. Global Ustekinumab Biosimilars Revenue Market Share by Region (2027-2032) Table 19. Global Ustekinumab Biosimilars Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units) Table 21. Global Ustekinumab Biosimilars Sales by Region (2027-2032) & (K Units) Table 22. Global Ustekinumab Biosimilars Sales Market Share by Region (2021-2026) Table 23. Global Ustekinumab Biosimilars Sales Market Share by Region (2027-2032) Table 24. Global Ustekinumab Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Ustekinumab Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Ustekinumab Biosimilars Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Ustekinumab Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 28. Global Ustekinumab Biosimilars Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Ustekinumab Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Ustekinumab Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Ustekinumab Biosimilars Manufacturers, Product Type & Application Table 32. Global Ustekinumab Biosimilars Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Ustekinumab Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Ustekinumab Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2026) Table 39. Global Ustekinumab Biosimilars Revenue Market Share by Type (2027-2032) Table 40. Global Ustekinumab Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 42. Global Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 43. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2026) Table 44. Global Ustekinumab Biosimilars Sales Market Share by Type (2027-2032) Table 45. Global Ustekinumab Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 46. Global Ustekinumab Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 47. Global Ustekinumab Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2026) Table 51. Global Ustekinumab Biosimilars Revenue Market Share by Application (2027-2032) Table 52. Global Ustekinumab Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 54. Global Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 55. Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2026) Table 56. Global Ustekinumab Biosimilars Sales Market Share by Application (2027-2032) Table 57. Global Ustekinumab Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 58. Global Ustekinumab Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 59. Teva Company Information Table 60. Teva Business Overview Table 61. Teva Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Teva Ustekinumab Biosimilars Product Portfolio Table 63. Teva Recent Development Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Amgen Ustekinumab Biosimilars Product Portfolio Table 68. Amgen Recent Development Table 69. Samsung Bioepis Company Information Table 70. Samsung Bioepis Business Overview Table 71. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Samsung Bioepis Ustekinumab Biosimilars Product Portfolio Table 73. Samsung Bioepis Recent Development Table 74. Sandoz Company Information Table 75. Sandoz Business Overview Table 76. Sandoz Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sandoz Ustekinumab Biosimilars Product Portfolio Table 78. Sandoz Recent Development Table 79. Biocon Biologics Company Information Table 80. Biocon Biologics Business Overview Table 81. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Biocon Biologics Ustekinumab Biosimilars Product Portfolio Table 83. Biocon Biologics Recent Development Table 84. Celltrion Company Information Table 85. Celltrion Business Overview Table 86. Celltrion Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Celltrion Ustekinumab Biosimilars Product Portfolio Table 88. Celltrion Recent Development Table 89. Qyuns Therapeutics Company Information Table 90. Qyuns Therapeutics Business Overview Table 91. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio Table 93. Qyuns Therapeutics Recent Development Table 94. Bio-Thera Solutions Company Information Table 95. Bio-Thera Solutions Business Overview Table 96. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio Table 98. Bio-Thera Solutions Recent Development Table 99. Huadong Medicine Company Information Table 100. Huadong Medicine Business Overview Table 101. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Huadong Medicine Ustekinumab Biosimilars Product Portfolio Table 103. Huadong Medicine Recent Development Table 104. North America Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 105. North America Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 106. North America Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 107. North America Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 108. North America Ustekinumab Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 109. North America Ustekinumab Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 110. North America Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 113. North America Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 114. North America Ustekinumab Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 115. North America Ustekinumab Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 116. North America Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America Ustekinumab Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 118. North America Ustekinumab Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 119. North America Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 120. North America Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 121. North America Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 122. North America Ustekinumab Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 123. North America Ustekinumab Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 124. United States Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 125. Canada Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 126. Mexico Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 127. Europe Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 130. Europe Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 131. Europe Ustekinumab Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 132. Europe Ustekinumab Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 133. Europe Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 136. Europe Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 137. Europe Ustekinumab Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 138. Europe Ustekinumab Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 139. Europe Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe Ustekinumab Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. Europe Ustekinumab Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. Europe Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. Europe Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 144. Europe Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 145. Europe Ustekinumab Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 146. Europe Ustekinumab Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 147. Germany Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 148. France Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 149. U.K. Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 150. Italy Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 151. Russia Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 152. Spain Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 153. Netherlands Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 154. Switzerland Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 155. Sweden Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 156. Poland Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 157. China Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 158. China Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 159. China Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 160. China Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 161. China Ustekinumab Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 162. China Ustekinumab Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 163. China Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 164. China Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 165. China Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 166. China Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 167. China Ustekinumab Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 168. China Ustekinumab Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Asia Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 172. Asia Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 173. Asia Ustekinumab Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 174. Asia Ustekinumab Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 175. Asia Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 176. Asia Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 177. Asia Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 178. Asia Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 179. Asia Ustekinumab Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 180. Asia Ustekinumab Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 181. Asia Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 182. Asia Ustekinumab Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 183. Asia Ustekinumab Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 184. Asia Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 185. Asia Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 186. Asia Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 187. Asia Ustekinumab Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 188. Asia Ustekinumab Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 189. Japan Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 190. South Korea Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 191. India Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 192. Australia Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 193. Taiwan Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 194. Southeast Asia Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 195. SAMEA Ustekinumab Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 196. SAMEA Ustekinumab Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 197. SAMEA Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 198. SAMEA Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 199. SAMEA Ustekinumab Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 200. SAMEA Ustekinumab Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 201. SAMEA Ustekinumab Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 202. SAMEA Ustekinumab Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 203. SAMEA Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 204. SAMEA Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 205. SAMEA Ustekinumab Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 206. SAMEA Ustekinumab Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 207. SAMEA Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. SAMEA Ustekinumab Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. SAMEA Ustekinumab Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. SAMEA Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 211. SAMEA Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 212. SAMEA Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 213. SAMEA Ustekinumab Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 214. SAMEA Ustekinumab Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Brazil Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 216. Argentina Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 217. Chile Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 218. Colombia Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 219. Peru Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 220. Saudi Arabia Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 221. Israel Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 222. UAE Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 223. Turkey Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 224. Iran Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 225. Egypt Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Table 226. Key Raw Materials Table 227. Raw Materials Key Suppliers Table 228. Ustekinumab Biosimilars Distributors List Table 229. Ustekinumab Biosimilars Customers List Table 230. Research Programs/Design for This Report Table 231. Authors List of This Report Table 232. Secondary Sources Table 233. Primary Sources List of Figures Figure 1. Ustekinumab Biosimilars Image Figure 2. Global Ustekinumab Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ustekinumab Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Subcutaneous Injection Image Figure 5. Intravenous Infusion Image Figure 6. Global Ustekinumab Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Ustekinumab Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Crohn's Disease Image Figure 9. Ulcerative Colitis Image Figure 10. Plaque Psoriasis Image Figure 11. Psoriatic Arthritis Image Figure 12. Other Image Figure 13. Global Ustekinumab Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Ustekinumab Biosimilars Revenue (2021-2032) & (US$ Million) Figure 15. Global Ustekinumab Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Ustekinumab Biosimilars Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Ustekinumab Biosimilars Revenue Market Share by Region (2021-2032) Figure 18. Global Ustekinumab Biosimilars Sales (2021-2032) & (K Units) Figure 19. Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Ustekinumab Biosimilars Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Ustekinumab Biosimilars Sales YoY (2021-2032) & (K Units) Figure 22. Europe Ustekinumab Biosimilars Sales YoY (2021-2032) & (K Units) Figure 23. China Ustekinumab Biosimilars Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Ustekinumab Biosimilars Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Ustekinumab Biosimilars Sales YoY (2021-2032) & (K Units) Figure 26. Global Ustekinumab Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Ustekinumab Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Ustekinumab Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Ustekinumab Biosimilars Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2032) Figure 32. Global Ustekinumab Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Ustekinumab Biosimilars Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2032) Figure 35. Global Ustekinumab Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Ustekinumab Biosimilars Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2032) Figure 38. Global Ustekinumab Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Ustekinumab Biosimilars Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2032) Figure 41. North America Ustekinumab Biosimilars Revenue Share by Type (2021-2032) Figure 42. North America Ustekinumab Biosimilars Sales Share by Type (2021-2032) Figure 43. North America Ustekinumab Biosimilars Revenue Share by Application (2021-2032) Figure 44. North America Ustekinumab Biosimilars Sales Share by Application (2021-2032) Figure 45. North America Ustekinumab Biosimilars Revenue Share by Country (2021-2032) Figure 46. North America Ustekinumab Biosimilars Sales Share by Country (2021-2032) Figure 47. Europe Ustekinumab Biosimilars Revenue Share by Type (2021-2032) Figure 48. Europe Ustekinumab Biosimilars Sales Share by Type (2021-2032) Figure 49. Europe Ustekinumab Biosimilars Revenue Share by Application (2021-2032) Figure 50. Europe Ustekinumab Biosimilars Sales Share by Application (2021-2032) Figure 51. Europe Ustekinumab Biosimilars Revenue Share by Country (2021-2032) Figure 52. Europe Ustekinumab Biosimilars Sales Share by Country (2021-2032) Figure 53. China Ustekinumab Biosimilars Revenue Share by Type (2021-2032) Figure 54. China Ustekinumab Biosimilars Sales Share by Type (2021-2032) Figure 55. China Ustekinumab Biosimilars Revenue Share by Application (2021-2032) Figure 56. China Ustekinumab Biosimilars Sales Share by Application (2021-2032) Figure 57. Asia Ustekinumab Biosimilars Revenue Share by Type (2021-2032) Figure 58. Asia Ustekinumab Biosimilars Sales Share by Type (2021-2032) Figure 59. Asia Ustekinumab Biosimilars Revenue Share by Application (2021-2032) Figure 60. Asia Ustekinumab Biosimilars Sales Share by Application (2021-2032) Figure 61. Asia Ustekinumab Biosimilars Revenue Share by Country (2021-2032) Figure 62. Asia Ustekinumab Biosimilars Sales Share by Country (2021-2032) Figure 63. SAMEA Ustekinumab Biosimilars Revenue Share by Type (2021-2032) Figure 64. SAMEA Ustekinumab Biosimilars Sales Share by Type (2021-2032) Figure 65. SAMEA Ustekinumab Biosimilars Revenue Share by Application (2021-2032) Figure 66. SAMEA Ustekinumab Biosimilars Sales Share by Application (2021-2032) Figure 67. SAMEA Ustekinumab Biosimilars Revenue Share by Country (2021-2032) Figure 68. SAMEA Ustekinumab Biosimilars Sales Share by Country (2021-2032) Figure 69. Ustekinumab Biosimilars Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Ustekinumab Biosimilars Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Teva
  • Amgen
  • Samsung Bioepis
  • Sandoz
  • Biocon Biologics
  • Celltrion
  • Qyuns Therapeutics
  • Bio-Thera Solutions
  • Huadong Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ustekinumab Biosimilars Market by Type
  3. 1.2.1 Global Ustekinumab Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Subcutaneous Injection
  5. 1.2.3 Intravenous Infusion
  6. 1.3 Ustekinumab Biosimilars Market by Application
  7. 1.3.1 Global Ustekinumab Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Crohn's Disease
  9. 1.3.3 Ulcerative Colitis
  10. 1.3.4 Plaque Psoriasis
  11. 1.3.5 Psoriatic Arthritis
  12. 1.3.6 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Ustekinumab Biosimilars Market Dynamics
  1. 2.1 Ustekinumab Biosimilars Industry Trends
  2. 2.2 Ustekinumab Biosimilars Industry Drivers
  3. 2.3 Ustekinumab Biosimilars Industry Opportunities and Challenges
  4. 2.4 Ustekinumab Biosimilars Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Ustekinumab Biosimilars Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Ustekinumab Biosimilars Revenue by Region
  3. 3.2.1 Global Ustekinumab Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ustekinumab Biosimilars Revenue by Region (2021-2026)
  5. 3.2.3 Global Ustekinumab Biosimilars Revenue by Region (2027-2032)
  6. 3.2.4 Global Ustekinumab Biosimilars Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Ustekinumab Biosimilars Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Ustekinumab Biosimilars Sales by Region
  9. 3.4.1 Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Ustekinumab Biosimilars Sales by Region (2021-2026)
  11. 3.4.3 Global Ustekinumab Biosimilars Sales by Region (2027-2032)
  12. 3.4.4 Global Ustekinumab Biosimilars Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Ustekinumab Biosimilars Revenue by Manufacturers
  2. 4.1.1 Global Ustekinumab Biosimilars Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Ustekinumab Biosimilars Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Ustekinumab Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ustekinumab Biosimilars Sales by Manufacturers
  6. 4.2.1 Global Ustekinumab Biosimilars Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Ustekinumab Biosimilars Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Ustekinumab Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Ustekinumab Biosimilars Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Ustekinumab Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Ustekinumab Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Ustekinumab Biosimilars Manufacturers, Product Type & Application
  13. 4.7 Global Ustekinumab Biosimilars Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Ustekinumab Biosimilars Market CR5 and HHI
  16. 4.8.2 2025 Ustekinumab Biosimilars Tier 1, Tier 2, and Tier 3
5 Ustekinumab Biosimilars Market by Type
  1. 5.1 Global Ustekinumab Biosimilars Revenue by Type
  2. 5.1.1 Global Ustekinumab Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Ustekinumab Biosimilars Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Ustekinumab Biosimilars Sales by Type
  6. 5.2.1 Global Ustekinumab Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Ustekinumab Biosimilars Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2032)
  9. 5.3 Global Ustekinumab Biosimilars Price by Type
6 Ustekinumab Biosimilars Market by Application
  1. 6.1 Global Ustekinumab Biosimilars Revenue by Application
  2. 6.1.1 Global Ustekinumab Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Ustekinumab Biosimilars Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Ustekinumab Biosimilars Sales by Application
  6. 6.2.1 Global Ustekinumab Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Ustekinumab Biosimilars Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2032)
  9. 6.3 Global Ustekinumab Biosimilars Price by Application
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Ustekinumab Biosimilars Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Amgen
  8. 7.2.1 Amgen Company Information
  9. 7.2.2 Amgen Business Overview
  10. 7.2.3 Amgen Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Ustekinumab Biosimilars Product Portfolio
  12. 7.2.5 Amgen Recent Developments
  13. 7.3 Samsung Bioepis
  14. 7.3.1 Samsung Bioepis Company Information
  15. 7.3.2 Samsung Bioepis Business Overview
  16. 7.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Samsung Bioepis Ustekinumab Biosimilars Product Portfolio
  18. 7.3.5 Samsung Bioepis Recent Developments
  19. 7.4 Sandoz
  20. 7.4.1 Sandoz Company Information
  21. 7.4.2 Sandoz Business Overview
  22. 7.4.3 Sandoz Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sandoz Ustekinumab Biosimilars Product Portfolio
  24. 7.4.5 Sandoz Recent Developments
  25. 7.5 Biocon Biologics
  26. 7.5.1 Biocon Biologics Company Information
  27. 7.5.2 Biocon Biologics Business Overview
  28. 7.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Biocon Biologics Ustekinumab Biosimilars Product Portfolio
  30. 7.5.5 Biocon Biologics Recent Developments
  31. 7.6 Celltrion
  32. 7.6.1 Celltrion Company Information
  33. 7.6.2 Celltrion Business Overview
  34. 7.6.3 Celltrion Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Celltrion Ustekinumab Biosimilars Product Portfolio
  36. 7.6.5 Celltrion Recent Developments
  37. 7.7 Qyuns Therapeutics
  38. 7.7.1 Qyuns Therapeutics Company Information
  39. 7.7.2 Qyuns Therapeutics Business Overview
  40. 7.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio
  42. 7.7.5 Qyuns Therapeutics Recent Developments
  43. 7.8 Bio-Thera Solutions
  44. 7.8.1 Bio-Thera Solutions Company Information
  45. 7.8.2 Bio-Thera Solutions Business Overview
  46. 7.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio
  48. 7.8.5 Bio-Thera Solutions Recent Developments
  49. 7.9 Huadong Medicine
  50. 7.9.1 Huadong Medicine Company Information
  51. 7.9.2 Huadong Medicine Business Overview
  52. 7.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Huadong Medicine Ustekinumab Biosimilars Product Portfolio
  54. 7.9.5 Huadong Medicine Recent Developments
8 North America
  1. 8.1 North America Ustekinumab Biosimilars Market Size by Type
  2. 8.1.1 North America Ustekinumab Biosimilars Revenue by Type (2021-2032)
  3. 8.1.2 North America Ustekinumab Biosimilars Sales by Type (2021-2032)
  4. 8.1.3 North America Ustekinumab Biosimilars Price by Type (2021-2032)
  5. 8.2 North America Ustekinumab Biosimilars Market Size by Application
  6. 8.2.1 North America Ustekinumab Biosimilars Revenue by Application (2021-2032)
  7. 8.2.2 North America Ustekinumab Biosimilars Sales by Application (2021-2032)
  8. 8.2.3 North America Ustekinumab Biosimilars Price by Application (2021-2032)
  9. 8.3 North America Ustekinumab Biosimilars Market Size by Country
  10. 8.3.1 North America Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Ustekinumab Biosimilars Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Ustekinumab Biosimilars Market Size by Type
  2. 9.1.1 Europe Ustekinumab Biosimilars Revenue by Type (2021-2032)
  3. 9.1.2 Europe Ustekinumab Biosimilars Sales by Type (2021-2032)
  4. 9.1.3 Europe Ustekinumab Biosimilars Price by Type (2021-2032)
  5. 9.2 Europe Ustekinumab Biosimilars Market Size by Application
  6. 9.2.1 Europe Ustekinumab Biosimilars Revenue by Application (2021-2032)
  7. 9.2.2 Europe Ustekinumab Biosimilars Sales by Application (2021-2032)
  8. 9.2.3 Europe Ustekinumab Biosimilars Price by Application (2021-2032)
  9. 9.3 Europe Ustekinumab Biosimilars Market Size by Country
  10. 9.3.1 Europe Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Ustekinumab Biosimilars Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Ustekinumab Biosimilars Market Size by Type
  2. 10.1.1 China Ustekinumab Biosimilars Revenue by Type (2021-2032)
  3. 10.1.2 China Ustekinumab Biosimilars Sales by Type (2021-2032)
  4. 10.1.3 China Ustekinumab Biosimilars Price by Type (2021-2032)
  5. 10.2 China Ustekinumab Biosimilars Market Size by Application
  6. 10.2.1 China Ustekinumab Biosimilars Revenue by Application (2021-2032)
  7. 10.2.2 China Ustekinumab Biosimilars Sales by Application (2021-2032)
  8. 10.2.3 China Ustekinumab Biosimilars Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ustekinumab Biosimilars Market Size by Type
  2. 11.1.1 Asia Ustekinumab Biosimilars Revenue by Type (2021-2032)
  3. 11.1.2 Asia Ustekinumab Biosimilars Sales by Type (2021-2032)
  4. 11.1.3 Asia Ustekinumab Biosimilars Price by Type (2021-2032)
  5. 11.2 Asia Ustekinumab Biosimilars Market Size by Application
  6. 11.2.1 Asia Ustekinumab Biosimilars Revenue by Application (2021-2032)
  7. 11.2.2 Asia Ustekinumab Biosimilars Sales by Application (2021-2032)
  8. 11.2.3 Asia Ustekinumab Biosimilars Price by Application (2021-2032)
  9. 11.3 Asia Ustekinumab Biosimilars Market Size by Country
  10. 11.3.1 Asia Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Ustekinumab Biosimilars Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ustekinumab Biosimilars Market Size by Type
  2. 12.1.1 SAMEA Ustekinumab Biosimilars Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Ustekinumab Biosimilars Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Ustekinumab Biosimilars Price by Type (2021-2032)
  5. 12.2 SAMEA Ustekinumab Biosimilars Market Size by Application
  6. 12.2.1 SAMEA Ustekinumab Biosimilars Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Ustekinumab Biosimilars Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Ustekinumab Biosimilars Price by Application (2021-2032)
  9. 12.3 SAMEA Ustekinumab Biosimilars Market Size by Country
  10. 12.3.1 SAMEA Ustekinumab Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Ustekinumab Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Ustekinumab Biosimilars Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Ustekinumab Biosimilars Value Chain Analysis
  2. 13.1.1 Ustekinumab Biosimilars Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Ustekinumab Biosimilars Production Mode & Process
  6. 13.2 Ustekinumab Biosimilars Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Ustekinumab Biosimilars Distributors
  9. 13.2.3 Ustekinumab Biosimilars Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst